Trials / Recruiting
RecruitingNCT06592274
A Phase 2 Study of HB0017 in Psoriasis Patients
A Multicenter, Randomized, Double-blind Phase 2 Clinical Study Evaluating the Efficacy and Safety of Different Administration Regimens of HB0017 Injection in Patients With Moderate to Severe Plaque Psoriasis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- Huabo Biopharm Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HB0017 | 300mg Q12W |
| BIOLOGICAL | HB0017 | 300mg Q8W |
| BIOLOGICAL | HB0017 | 150mg Q4W |
Timeline
- Start date
- 2024-09-30
- Primary completion
- 2025-04-30
- Completion
- 2026-01-30
- First posted
- 2024-09-19
- Last updated
- 2025-09-15
Locations
18 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06592274. Inclusion in this directory is not an endorsement.